Improving adherence rates to a cocooning program: A pilot experience in Italy

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 9, Issue 5  May 2013
http://www.landesbioscience.com/journals/vaccines/toc/volume/9/issue/5/

Short Report
Improving adherence rates to a cocooning program: A pilot experience in Italy
Volume 9, Issue 5   May 2013
http://dx.doi.org/10.4161/hv.23795
Vairo, Pasquale Piscopo and Federico Marchetti

Abstract:
Cocoon is defined as a strategy to reduce the risk for transmission of pertussis to newborn infants by vaccinating household members including parents and siblings. Programmatic challenges make implementation of cocooning program complex. At the local health care unit “ASL Napoli 1 Centro,” a one-year pilot project to evaluate the newborn contacts adherence to a cocoon strategy was started on May, 1st 2011. Healthcare providers (HCPs) offered for free a dTpa booster dose to newborns parents (mothers were immunized after delivery) and household contacts. Until June 30th, overall only 7 dTpa booster doses out of 261 newborns (2.6%) were administered for cocooning. Then, an improvement in communication strategy to the families was introduced by preparing specific information leaflets, increasing the HCPs devoted to the cocoon, and focusing the interaction with families during the visiting time at the maternity ward. Overall, 601 out of 762 (78,8%) contacted new mothers received dTpa booster. Cocoon high acceptance rates could be reached providing that proper communication tools and enough skilled HCPs were engaged in the interaction with the families. This report is, to our knowledge, the first to document successful implementation of pertussis cocooning in an Italian setting.

http://www.landesbioscience.com/journals/vaccines/article/23795/

Using risk to target HPV vaccines in high-risk, low-resource organizations

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 9, Issue 5  May 2013
http://www.landesbioscience.com/journals/vaccines/toc/volume/9/issue/5/

Research Paper
Using risk to target HPV vaccines in high-risk, low-resource organizations
Volume 9, Issue 5   May 2013
http://dx.doi.org/10.4161/hv.23456
Stephanie L. Small, Carolyn M. Sampselle, Kristy K. Martyn and Amanda F. Dempsey

Abstract:
Organizations in developed countries with limited financial resources may find it difficult to determine whether it is preferable to use these resources for HPV vaccination, management of HPV-related diseases, or a “hybrid” strategy, such as vaccinating only the highest risk individuals. We determined the organizational costs and clinical impacts of three different organizational approaches to female HPV vaccination in a low-resource setting, including vaccinating everyone, vaccinating no one, or vaccinating only those considered high-risk. To determine patients at highest risk, HPV risk factors were identified using information routinely gathered at the annual preventive maintenance visit. The three vaccination strategies were then compared using a decision tree analysis. The three strategies demonstrated very little difference in cost. However, the least expensive strategy was to vaccinate no one. In contrast, the strategy with the best clinical outcomes was for the organization to vaccinate everyone. Organizations with limited resources must decide how to best allocate these funds to provide the greatest clinical benefits. This study showed little difference in costs but improved clinical outcomes when using the universal HPV vaccination strategy. Thus, the improvement in clinical outcomes when vaccinating everyone may be worth the relatively small increase in cost of vaccinating everyone.

http://www.landesbioscience.com/journals/vaccines/article/23456/

Vaccination against herpes zoster in developed countries: State of the evidence

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 9, Issue 5  May 2013
http://www.landesbioscience.com/journals/vaccines/toc/volume/9/issue/5/

Commentary
Vaccination against herpes zoster in developed countries: State of the evidence
Mélanie Drolet, Michael N. Oxman, Myron J. Levin, Kenneth E. Schmader, Robert W. Johnson, David Patrick, James A. Mansi and Marc Brisson

Abstract:
Although progress has been made in the treatment of herpes zoster (HZ) and postherpetic neuralgia (PHN), available therapeutic options are only partially effective. Given evidence that a live-attenuated varicella-zoster-virus vaccine is effective at reducing the incidence of HZ, PHN and the burden of illness, policymakers and clinicians are being asked to make recommendations regarding the use of the zoster vaccine. In this report, we summarize the evidence regarding the: (1) burden of illness; (2) vaccine efficacy and safety; and (3) cost-effectiveness of vaccination, to assist evidence-based policy making and guide clinicians in their recommendations. First, there is general agreement that the overall burden of illness associated with HZ and PHN is substantial. Second, the safety and efficacy of the zoster vaccine at reducing the burden of illness due to HZ and the incidence of PHN have been clearly demonstrated in large placebo-controlled trials. However, uncertainty remains about the vaccine’s duration of protection. Third, vaccination against HZ is likely to be cost-effective when the vaccine is given at approximately 65 y of age, if vaccine duration is longer than 10 y.
http://www.landesbioscience.com/journals/vaccines/article/23491/

Inferring the potential risks of H7N9 infection by spatiotemporally characterizing bird migration and poultry distribution in eastern China

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 4 May 2013]

Research Article
Inferring the potential risks of H7N9 infection by spatiotemporally characterizing bird migration and poultry distribution in eastern China
Benyun Shi, Shang Xia, Guo-Jing Yang, Xiao-Nong Zhou and Jiming Liu
Infectious Diseases of Poverty 2013, 2:8 doi:10.1186/2049-9957-2-8
Published: 3 May 2013

Abstract (provisional)
Background
In view of the rapid geographic spread and the increased number of confirmed cases of novel influenza A(H7N9) virus infections in eastern China, we developed a diffusion model to spatiotemporally characterize the impacts of bird migration and poultry distribution on the geographic spread of H7N9 infection.

Methods
The three types of infection risks were estimated for 12 weeks, from February 4 to April 28, 2013, including (i) the risk caused by bird migration, (ii) the risk caused by poultry distribution, and (iii) the integrated risk caused by both bird migration and poultry distribution. To achieve this, we first developed a method for estimating the likelihood of bird migration based on available environmental and meteorological data. Then, we adopted a computational mobility model to estimate poultry distribution based on annual poultry production and consumption of each province/municipality. Finally, the spatiotemporal risk maps were created based on the integrated impact of both bird migration and poultry distribution.

Results
In the study of risk estimation caused by bird migration, the likelihood matrix was estimated based on the 7-day temperature, from February 4 to April 28, 2013. It was found the estimated migrant birds mainly appear in the southeastern provinces of Zhejiang, Shanghai and Jiangsu during Weeks 1 to 4, and Week 6, followed by appear in central eastern provinces of Shandong, Hebei, Beijing, and Tianjin during Weeks 7 to 9, and finally appear in northeastern provinces of Liaoning, Jilin, and Heilongjiang during Weeks 10 to 12. In the study of risk estimation caused by bird migration, the likelihood matrix was estimated based on the 7-day temperature, from February 4 to April 28, 2013. It was found the estimated migrant birds mainly appear in the southeastern provinces of Zhejiang, Shanghai and Jiangsu during Weeks 1 to 4, and Week 6, followed by appearing in central eastern provinces of Shandong, Hebei, Beijing, and Tianjin during Weeks 7 to 9, and finally appear in northeastern provinces of Liaoning, Jilin, and Heilongjiang during Weeks 10 to 12.

In the study of risk caused by poultry distribution, poultry distribution matrix was created to show the probability of poultry distribution. Although the fact that the majority of the initial infections are reported in Shanghai and Jiangsu province, the relative risk of H7N9 infection estimated based on the poultry distribution model predicted that Jiangsu may have a slightly higher likelihood of H7N9 infection than that in Zhejiang and Shanghai, if we only take the probability of poultry distribution into consideration.

In the study of integrated risk caused by both bird migration and poultry distribution, the higher risk in southeastern provinces occurred during the first 8 weeks, and that in central eastern provinces appeared during Weeks 8 to 12, and that in northeastern provinces since Week 12. Therefore, it is necessary to regulate the poultry markets as long as the poultry-to-poultry transmission is not so well understood.

Conclusion
With reference to the reported infection cases, the demonstrated risk mapping results will provide guidance in active surveillance and control of human H7N9 infections by taking intensive intervention in poultry markets.
http://www.idpjournal.com/content/2/1/8/abstract

JAMA: Transformation of Child Health Research

JAMA   
May 01, 2013, Vol 309, No. 17
http://jama.ama-assn.org/current.dtl

Viewpoint | May 01, 2013
The Transformation of Child Health Research: Innovation, Market Failure, and the Public Good
Barbara J. Stoll, MD; David K. Stevenson, MD; Paul H. Wise, MD, MPH
JAMA. 2013;309(17):1779-1780. doi:10.1001/jama.2013.3257.

Excerpt
Despite a remarkable record of accomplishments, the pediatric research community faces mounting evidence that the nature and scope of current research are inadequate. The Editorial “Challenges to Excellence in Child Health Research,” by Zylke et al,1 casts this paradox in sharp relief by summarizing a series of articles suggesting that the quality and number of pediatric research studies lag behind research focused on adults. For measurable and sustainable gains in child health, pediatric research should be informed by the changing epidemiology of childhood illness, the need to monitor both survival and long-term outcomes, and the increasing recognition of pediatric origins of adult chronic disease and social determinants of health. Recent advances in genetics, imaging, and bioinformatics provide new venues for productive research. Moreover, the status of children in society must be elevated and the political will necessary to provide adequate financial support for research enhanced.
http://jama.jamanetwork.com/article.aspx?articleid=1682950

Editorial | May 01, 2013
Contrasts in Child Health Care and Child Health Research
Jody W. Zylke, MD; Frederick P. Rivara, MD, MPH; Howard Bauchner, MD
JAMA. 2013;309(17):1834-1836. doi:10.1001/jama.2013.4284.
http://jama.jamanetwork.com/article.aspx?articleid=1682921

Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women: A Randomized Clinical Trial

JAMA   
May 01, 2013, Vol 309, No. 17
http://jama.ama-assn.org/current.dtl

Original Contribution | May 01, 2013
Immunogenicity of 2 Doses of HPV Vaccine in Younger Adolescents vs 3 Doses in Young Women: A Randomized Clinical Trial
Simon R. M. Dobson, MD; Shelly McNeil, MD; Marc Dionne, MD; Meena Dawar, MD; Gina Ogilvie, MD; Mel Krajden, MD, PhD; Chantal Sauvageau, MD; David W. Scheifele, MD; Tobias R. Kollmann, MD, PhD; Scott A. Halperin, MD; Joanne M. Langley, MD; Julie A. Bettinger, PhD; Joel Singer, PhD; Deborah Money, MD; Dianne Miller, MD; Monika Naus, MD; Fawziah Marra, PharmD; Eric Young, MD
[+] Author Affiliations
JAMA. 2013;309(17):1793-1802. doi:10.1001/jama.2013.1625.

ABSTRACT
Importance
Global use of human papillomavirus (HPV) vaccines to prevent cervical cancer is impeded by cost. A 2-dose schedule for girls may be possible.

Objective
To determine whether mean antibody levels to HPV-16 and HPV-18 among girls receiving 2 doses was noninferior to women receiving 3 doses.

Design, Setting, and Patients
Randomized, phase 3, postlicensure, multicenter, age-stratified, noninferiority immunogenicity study of 830 Canadian females from August 2007 through February 2011. Follow-up blood samples were provided by 675 participants (81%).

Intervention
Girls (9-13 years) were randomized 1:1 to receive 3 doses of quadrivalent HPV vaccine at 0, 2, and 6 months (n = 261) or 2 doses at 0 and 6 months (n = 259). Young women (16-26 years) received 3 doses at 0, 2, and 6 months (n = 310). Antibody levels were measured at 0, 7, 18, 24, and 36 months.

Main Outcomes and Measures
Primary outcome was noninferiority (95% CI, lower bound >0.5) of geometric mean titer (GMT) ratios for HPV-16 and HPV-18 for girls (2 doses) compared with young women (3 doses) 1 month after last dose. Secondary outcomes were noninferiority of GMT ratios of girls receiving 2 vs 3 doses of vaccine; and durability of noninferiority to 36 months.

Results
The GMT ratios were noninferior for girls (2 doses) to women (3 doses): 2.07 (95% CI, 1.62-2.65) for HPV-16 and 1.76 (95% CI, 1.41-2.19) for HPV-18. Girls (3 doses) had GMT responses 1 month after last vaccination for HPV-16 of 7736 milli-Merck units per mL (mMU/mL) (95% CI, 6651-8999) and HPV-18 of 1730 mMU/mL (95% CI, 1512-1980). The GMT ratios were noninferior for girls (2 doses) to girls (3 doses): 0.95 (95% CI, 0.73-1.23) for HPV-16 and 0.68 (95% CI, 0.54-0.85) for HPV-18. The GMT ratios for girls (2 doses) to women (3 doses) remained noninferior for all genotypes to 36 months. Antibody responses in girls were noninferior after 2 doses vs 3 doses for all 4 vaccine genotypes at month 7, but not for HPV-18 by month 24 or HPV-6 by month 36.

Conclusions and Relevance
Among girls who received 2 doses of HPV vaccine 6 months apart, responses to HPV-16 and HPV-18 one month after the last dose were noninferior to those among young women who received 3 doses of the vaccine within 6 months. Because of the loss of noninferiority to some genotypes at 24 to 36 months in girls given 2 doses vs 3 doses, more data on the duration of protection are needed before reduced-dose schedules can be recommended.

Trial Registration  clinicaltrials.gov Identifier: NCT00501137
http://jama.jamanetwork.com/article.aspx?articleid=1682939

Editorial | May 01, 2013
HPV Vaccination Too Soon for 2 Doses?
Jessica A. Kahn, MD, MPH; David I. Bernstein, MD, MA
JAMA. 2013;309(17):1832-1834. doi:10.1001/jama.2013.4147.

Excerpt
Cervical cancer is the second most common cancer among women globally, according to age-standardized incidence rates.1 Approximately 530 000 women are diagnosed with cervical cancer and 275 000 die of the disease every year; 88% of deaths occur in developing regions of the world.1 Human papillomavirus (HPV) infection is a well-established cause of cervical cancer as well as other anogenital and oropharyngeal cancers; therefore, prophylactic HPV vaccines have the potential to substantially reduce the incidence of cervical cancer and other HPV-associated diseases.2 Three-dose schedules of the bivalent vaccine (HPV-16 and -18) and the quadrivalent vaccine (HPV-6, -11, -16, and -18) have been shown to be highly efficacious in preventing persistent infection with HPV-16 and -18, which cause approximately 70% of cervical cancers, as well as precancerous lesions associated with these types.3- 5 The quadrivalent vaccine has also been shown to prevent anogenital warts associated with HPV-6 and -11.3,5
http://jama.jamanetwork.com/article.aspx?articleid=1682919

Health Information During the H1N1 Influenza Pandemic: Did the Amount Received Influence Infection Prevention Behaviors?

Journal of Community Health
Volume 38, Issue 3, June 2013
http://link.springer.com/journal/10900/38/3/page/1

Health Information During the H1N1 Influenza Pandemic: Did the Amount Received Influence Infection Prevention Behaviors?
Bella Etingen, Sherri L. LaVela, Scott Miskevics, Barry Goldstein

Abstract
In the wake of uncertainty due to the H1N1 influenza pandemic, amount and sources of H1N1-related information were examined in a cohort at high-risk for respiratory complications. Factors associated with adequate amount of information were identified. A cross-sectional mailed survey was conducted in 2010 with veterans with spinal cord injuries and disorders. Bivariate comparisons assessed adequate H1N1-realted information versus not enough and too much. Multivariate regression identified variables associated with receipt of adequate information. A greater proportion who received adequate versus not enough information received H1N1 vaccination (61.87 vs. 48.49 %, p < 0.0001). A greater proportion who received adequate versus too much information received seasonal vaccination (84.90 vs. 71.02 %, p < 0.0001) and H1N1 vaccination (61.87 vs. 42.45 %, p < 0.0001). Variables associated with greater odds of receiving adequate information included being white, a college graduate, and having VA health professionals as their primary information source. Receiving adequate information was associated with lower odds of staying home with flu/flu-like symptoms, and higher odds of H1N1 vaccine receipt and wearing a facemask. Receiving appropriate amounts of information from valid sources may impact adherence to infection control recommendations during pandemics. Findings can be used to facilitate efforts ensuring information is received by high-risk populations.

http://link.springer.com/article/10.1007/s10900-012-9647-8

Comment: Linking child survival and child development for health, equity, and sustainable development

The Lancet  
May 04, 2013  Volume 381  Number 9877  p1511 – 1596
http://www.thelancet.com/journals/lancet/issue/current

Comment
Linking child survival and child development for health, equity, and sustainable development
Margaret Chan

Preview
Considerable progress has been made over the past decade towards Millennium Development Goal 4. The number of deaths among children younger than 5 years has declined from 12 million in 1990 to 6·9 million in 2011.1 But do the surviving children have an equal chance to realise their human potential, achieve social justice, and contribute to sustainable development? The global community has an obligation to ensure that all children develop to full capacity, not only as a human right but also for equitable prosperity and sustainable progress of societies.

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2960944-7/fulltext

Comment: Poliomyelitis in Pakistan: time for the Muslim world to step in

The Lancet  
May 04, 2013  Volume 381  Number 9877  p1511 – 1596
http://www.thelancet.com/journals/lancet/issue/current

Comment
Poliomyelitis in Pakistan: time for the Muslim world to step in
Qanta A Ahmed, Sania Nishtar, Ziad A Memish

Preview
Global poliomyelitis eradication is almost within reach—this disease persists only in Nigeria, Afghanistan, and Pakistan, which are countries with substantial Muslim populations.1 Today this ambitious goal is threatened, partly by misinformed and politicised religious views that not only seed suspicion about polio vaccination but recently led to murder of polio workers. In Pakistan, 16 workers engaged in a polio vaccination campaign have been killed since December, 2012, halting vaccination in many parts of the country and placing Pakistan’s 2012 gains in poliomyelitis eradication at risk.

Long-term Effectiveness of Varicella Vaccine: A 14-Year, Prospective Cohort Study

Pediatrics
May 2013, VOLUME 131 / ISSUE 5
http://pediatrics.aappublications.org/current.shtml

Article
Long-term Effectiveness of Varicella Vaccine: A 14-Year, Prospective Cohort Study
Roger Baxter, MDa, Paula Ray, MPHa, Trung N. Tran, MD, PhDb, Steve Black, MDc, Henry R. Shinefield, MDd, Paul M. Coplan, ScD, MBAe, Edwin Lewis, MPHa, Bruce Fireman, MAa, and     Patricia Saddier, MD, PhDb

Abstract
BACKGROUND: Varicella vaccine was licensed in the United States in 1995 for individuals ≥12 months of age. A second dose was recommended in the United States in June 2006. Varicella incidence and vaccine effectiveness were assessed in a 14-year prospective study conducted at Kaiser Permanente Northern California.

METHODS: A total of 7585 children vaccinated with varicella vaccine in their second year of life in 1995 were followed up prospectively for breakthrough varicella and herpes zoster (HZ) through 2009. A total of 2826 of these children received a second dose in 2006–2009. Incidences of varicella and HZ were estimated and compared with prevaccine era rates.

RESULTS: In this cohort of vaccinated children, the average incidence of varicella was 15.9 per 1000 person-years, nine- to tenfold lower than in the prevaccine era. Vaccine effectiveness at the end of the study period was 90%, with no indication of waning over time. Most cases of varicella were mild and occurred early after vaccination. No child developed varicella after a second dose. HZ cases were mild, and rates were lower in the cohort of vaccinated children than in unvaccinated children during the prevaccine era (relative risk: 0.61 [95% confidence interval: 0.43–0.89]).

CONCLUSIONS: This study confirmed that varicella vaccine is effective at preventing chicken pox, with no waning noted over a 14-year period. One dose provided excellent protection against moderate to severe disease, and most cases occurred shortly after the cohort was vaccinated. The study data also suggest that varicella vaccination may reduce the risks of HZ in vaccinated children.

http://pediatrics.aappublications.org/content/131/5/e1389.abstract

The Impact of Social Networks on Parents’ Vaccination Decision

Pediatrics
May 2013, VOLUME 131 / ISSUE 5
http://pediatrics.aappublications.org/current.shtml

Article
The Impact of Social Networks on Parents’ Vaccination Decisions
Emily K. Brunson, MPH, PhD
Department of Anthropology, Texas State University, San Marcos, Texas

Abstract
BACKGROUND AND OBJECTIVE: Parents decide whether their children are vaccinated, but they rarely reach these decisions on their own. Instead parents are influenced by their social networks, broadly defined as the people and sources they go to for information, direction, and advice. This study used social network analysis to formally examine parents’ social networks (people networks and source networks) related to their vaccination decision-making. In addition to providing descriptions of typical networks of parents who conform to the recommended vaccination schedule (conformers) and those who do not (nonconformers), this study also quantified the effect of network variables on parents’ vaccination choices.

METHODS: This study took place in King County, Washington. Participation was limited to US-born, first-time parents with children aged ≤18 months. Data were collected via an online survey. Logistic regression was used to analyze the resulting data.

RESULTS: One hundred twenty-six conformers and 70 nonconformers completed the survey. Although people networks were reported by 95% of parents in both groups, nonconformers were significantly more likely to report source networks (100% vs 80%, P < .001). Model comparisons of parent, people, and source network characteristics indicated that people network variables were better predictors of parents’ vaccination choices than parents’ own characteristics or the characteristics of their source networks. In fact, the variable most predictive of parents’ vaccination decisions was the percent of parents’ people networks recommending nonconformity.

CONCLUSIONS: These results strongly suggest that social networks, and particularly parents’ people networks, play an important role in parents’ vaccination decision-making.

http://pediatrics.aappublications.org/content/131/5/e1397.abstract

Editorial: Focusing the Spotlight on Lack of Access to Health Information

PLoS Medicine
(Accessed 4 May 2013)
http://www.plosmedicine.org/

Editorial
Focusing the Spotlight on Lack of Access to Health Information
The PLoS Medicine Editors
http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001438
Published: April 30, 2013
Copyright: © 2013 PLOS Medicine Editors. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors are each paid a salary by the Public Library of Science, and they wrote this editorial during their salaried time.
Competing interests: The authors’ individual competing interests are at http://www.plosmedicine.org/static/edito​rsInterests.action. PLOS is funded partly through manuscript publication charges, but the PLOS Medicine Editors are paid a fixed salary (their salary is not linked to the number of papers published in the journal). PLOS is a HIFA 2015 financial supporting organisation and has actively contributed to HIFA 2015 webinars.

“In the 21st century, knowledge is the key element to improving health. In the same way that people need clean, clear water, they have a right to clean, clear knowledge” [1]. This is how Sir Muir Gray, Director of the UK’s National Health Service (NHS) National Knowledge Service, describes the importance of health knowledge. Knowledge underpins every medical advance, every intervention, and every clinical decision. However, access to reliable health information for even the most basic health needs remains elusive for much of the world’s population.

Access to reliable health information remains a problem even in settings where clean water is taken for granted. Despite the recognition of the importance of evidence-based health information, the problems of publication bias [2], missing trial data [3], influence from commercial organizations [4], and distortion of study implications [5] are well known and continue to haunt medical science and the information available to health workers and the general public. In addition to these challenges to the medical evidence, the process of translating available knowledge into appropriate action is a complex and ongoing endeavor [6].

It is in the poorest settings where basic health information may prove most valuable. For example, postpartum hemorrhage (PPH) is a leading cause of maternal death worldwide; yet despite being recommended by the WHO and other professional bodies, active management of the third stage of labor to prevent PPH was found to be correctly used in only 0.5% to 32% of observed deliveries in seven developing countries [7]. Worryingly, six of the seven countries were found to have multiple guidelines and conflicting recommendations for active management of the third stage of labor [7]. While lack of reliable information may well be a symptom of a weak health system in the most extreme cases, it can be the result of misinformation. It has been estimated that more than 330,000 lives were lost between 2000 and 2005 because the then-government of South Africa questioned whether HIV was the cause of AIDS, and they failed to implement a feasible and timely antiretroviral treatment program [8].

Medical journals remain a key part of the knowledge translation process, almost exclusively dealing with the final stages of knowledge creation (primary research), distillation (systematic reviews and guidelines), and commentary (editorializing and contextualizing by experts) via peer review and finally dissemination. Although making research openly available to be both read and reused is an essential step toward a vision of wider access to healthcare knowledge, disseminating information on its own is not enough to ensure evidence is used in decision-making [9]. In many settings it is access to secondary reference and educational materials based on the best available evidence that is severely lacking yet probably more crucial for clinical practice than the most recent observational study or clinical trial findings.

Organizations such as the WHO among others play an important role in providing reliable healthcare information. However, in low- and middle-income countries, such information is often not available where it is needed, or the information is not usable because it is in the wrong language or because it does not match the context or level of education of the healthcare provider.

In a recently published white paper, Neil Pakenham-Walsh and Molly Land argue that, because access to health information is a key determinant to the human right to the highest attainable standard of health, governments have a legal responsibility under international human rights law to provide access to healthcare information to citizens and health workers [10]. That is not to say that governments are required to generate this information, but they must ensure its availability and an enabling policy environment that does not hinder access to health information. States should provide access to information about health services and health policy so that a country’s citizens can access those services when needed and the educational health needs of both the general population and health workers are met.

If governments are legally obliged to enable access to reliable health information, what can be done to ensure that they do so? It is unlikely that governments will be held legally responsible for not ensuring that health information is available to their citizens and health workers, and a legal approach would be inappropriate in most cases. Furthermore, it is unrealistic to expect governments to react quickly to calls for change. However, by placing access to reliable health information into the broader human rights framework it may be possible to benefit from the momentum already generated by human rights organizations.

One model that has been effectively used by organizations such as Human Rights Watch (www.hrw.org) and Amnesty International (www.amnesty.org) to promote change is holding up a light to practices of governments, raising awareness of where they fail to meet their responsibilities. Healthcare Information for All by 2015 (HIFA2015) has taken this approach by setting up a campaign called HIFA-Watch (http://www.hifa2015.org/hifa-watch/). The campaign aims to highlight positive examples, such as recent legislation in Pakistan to ensure that commercial companies cannot claim that formula milk is a substitute for breast milk [11], as well as negative examples of government practices, such as countries that do not legally require pictorial warnings on tobacco products [12]. Of course, a webpage alone will not ensure change, and research into the practices of individual governments and sustained momentum are needed in order for the campaign to be a success.

The challenge of improving healthcare information in countries with meager resources will require more than just highlighting insufficiencies. Access to health information is a key component of a strong health system, but to be effective it requires evaluation and synthesis of evidence, translation of evidence into educational materials, and implementation and dissemination. Health information is one key component of the complex task of improving weak health systems, along with cooperation, political will, and funding.

Acknowledgments

The authors thank Neil Pakenham-Walsh for a helpful discussion and comments on a draft of this manuscript.

Author Contributions

Wrote the first draft of the manuscript: PS. Contributed to the writing of the manuscript: VB JC LC AR PS EV MW. ICMJE criteria for authorship read and met: VB JC LC AR PS EV MW. Agree with manuscript results and conclusions: VB JC LC AR PS EV MW.

References

1. NHS Choices (2011) What is behind the headlines? Available: http://www.nhs.uk/news/Pages/about-behin​d-the-headlines.aspx.Accessed 17 March 2013.

2. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B (2003) Evidence b(i)ased medicine—selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 326: 1171–1173. doi: 10.1136/bmj.326.7400.1171. Find this article online

3. Lee K, Bacchetti P, Sim I (2008) Publication of clinical trials supporting successful new drug applications: A literature analysis. PLoS Med 5: e191 doi:10.1371/journal.pmed.0050191. . doi: 10.1371/journal.pmed.0050191.

4. Sismondo S (2007) Ghost management: How much of the medical literature is shaped behind the scenes by the pharmaceutical industry? PLoS Med 4: e286 doi:10.1371/journal.pmed.0040286. . doi: 10.1371/journal.pmed.0040286.

5. Yavchitz A, Boutron I, Bafeta A, Marroun I, Charles P, et al. (2012) Misrepresentation of randomized controlled trials in press releases and news coverage: A cohort study. PLoS Med 9: e1001308 doi:10.1371/journal.pmed.1001308. . doi: 10.1371/journal.pmed.1001308.

6. Kitson A, Straus SE (2010) The knowledge-to-action cycle: identifying the gaps. CMAJ 182: E73–E77 doi:10.1503/cmaj.081231. . doi: 10.1503/cmaj.081231.

7. Stanton C, Armbruster D, Knight R, Ariawan I, Gbangbade S, et al. (2009) Use of active management of the third stage of labour in seven developing countries. Bull World Health Organ 87: 207–215 doi:10.2471/BLT.08.052597. . doi: 10.2471/BLT.08.052597.

8. Chigwedere P, Seage GR 3rd, Gruskin S, Lee TH, Essex M (2008) Estimating the lost benefits of antiretroviral drug use in South Africa. J Acquir Immune Defic Syndr 49: 410–415. doi: 10.1097/QAI.0b013e31818a6cd5. Find this article online

9. Straus SE, Tetroe J, Graham I (2009) Defining knowledge translation. CMAJ 181: 165–168. doi: 10.1503/cmaj.081229. Find this article online

10. New York Law School (2012) Access to health information under international human rights law. White paper series 11/12 #01. Available: http://www.nyls.edu/user_files/1/2/23/14​4/1345/Access%20to%20Health%20Informatio​n%20White%20Paper.pdf. Accessed 17 March 2013..

11. Murtaza A (2013) PAKISTAN: Important legislation to restrict infant formula milk manufactures. Available: http://www.humanrights.asia/opinions/col​umns/AHRC-ETC-010-2013. Accessed 20 March 2013.

12. Cunningham R (2010) Cigarette package warning size and use of pictures: International summary. Available: http://www.tobaccolabels.ca/labelima/hea​lthwarn. Accessed 20 March 2013.

WHO Preferred Product Characteristics for Malaria Vaccines: Bridging Vaccine R&D with Public Health

WHO Preferred Product Characteristics for Malaria Vaccines: Bridging Vaccine R&D with Public Health
V Moorthy – SAGE, 11 Apr 2013

Excerpt
Updated Vision
Safe and effective vaccines against Plasmodium falciparum and Plasmodium vivax that prevent transmission, disease and death to enable malaria eradication.

Updated Strategic Goals
By 2030, license vaccines targeting Plasmodium falciparum and Plasmodium vivax and encompassing the following two goals, for use by the international public health community:
–       Malaria vaccines with a protective efficacy of at least 70-80 % against clinical malaria, suitable for administration to appropriate at risk groups in malaria-endemic areas.
–       Malaria vaccines that reduce transmission of the parasite and thereby substantially reduce the incidence of human malaria infection. This will enable elimination in multiple settings.

Price discrimination and bargaining power in the global vaccine market

Price discrimination and bargaining power in the global vaccine market
[PDF] 2013
Linda Li
Professor David Ridley, Faculty Advisor
Honors Thesis submitted in partial fulfillment of the requirements for Graduation with Distinction in Economics in Trinity College of Duke University

Abstract
Since the 1980s, the market structure of vaccines has become increasingly oligopolistic, and in some cases, monopolistic. Alongside these supply trends, we see the emergence and growth of group procurement schemes on the demand side of the market. National governments and international organizations procure vaccines on behalf of end users. Two such organizations include the UNICEF Supply Division and the PAHO EPI Revolving Fund, for which participation is based on income or geography. Consistent with one of the main goals of group procurement, these groups obtain price discounts on vaccines relative to the private sector. This paper seeks to disentangle two possible explanations for this observed price dispersion using vaccine price data over the years 2002-2012 from UNICEF, PAHO, and the U.S. The two explanations are that of price discrimination and bargaining power. Using proxy variables in a fixed effects model, I find that price discrimination does have a significant impact on price discount. I also find support for a bargaining power effect, however, with less certainty, and the existence of supply constraints. These findings have important policy implications for national governments, as well as procurement groups.

Al Jazerra: The fight for global immunisation

Al Jazeera
26 April 2013
Inside Story
The fight for global immunisation
Can funding keep pace with the will to vaccinate every child worldwide?

Excerpt
It is universally recognised as one of the most successful and cost effective health programmes in the world. Immunising children against a range of diseases that can cause serious illness, disability or death.

The World Health Organization (WHO) estimates that immunisation prevents up to three million deaths every year, but it says an estimated 22 million children worldwide are missing out on basic vaccines.

And the children’s charity UNICEF says 4,000 children will die every day and many more will fall ill from diseases that can be prevented from a simple vaccination…

(TV interviews of Kate Elder, Adel Mahmoud)

http://www.aljazeera.com/programmes/insidestory/2013/04/201342682033272868.html

‘Manipulation’ of vaccination fears – Dr Seth Berkley, CEO of the GAVI Alliance

BBC
http://www.bbc.co.uk/
Accessed 4 May 2013
2 May 2013 Last updated at 22:15 ET

‘Manipulation’ of vaccination fears
By Dr Seth Berkley CEO of the GAVI Alliance
  Most parents who opt-out of vaccinations are being guided by “irrational fears” that are a luxury of living in the developed world, a leading world health expert says.
   In this week’s Scrubbing Up, Dr Seth Berkley, CEO of the GAVI Alliance – which provides children in developing countries with access to vaccines – says there is a real danger such fears will trickle down into the developing world where lives are even more vulnerable….
http://www.bbc.co.uk/news/health-22384788

Is It Crazy to Think We Can Eradicate Poverty? [by 2030] World Bank

New York Times
http://www.nytimes.com/
Accessed 4 May 2013

It’s the Economy
Is It Crazy to Think We Can Eradicate Poverty?
By ANNIE LOWREY
Published: April 30, 2013

At a news conference during the spring meetings of the International Monetary Fund and the World Bank in late April, Jim Yong Kim held up a piece of paper with the year “2030” scribbled on it in pen. “This is it,” said Kim, the genial American physician who took over as president of the World Bank last summer. “This is the global target to end poverty.”…

http://www.nytimes.com/2013/05/05/magazine/is-it-crazy-to-think-we-can-eradicate-poverty.html?_r=1&

WSJ: Glaxo Mined Online Parent Discussion Boards For Vaccine Worries

Wall Street Journal
http://online.wsj.com/home-page
Accessed 4 May 2013
May 1, 2013, 8:50 PM ET

Glaxo Mined Online Parent Discussion Boards For Vaccine Worries
The U.K. pharmaceutical company used text analytics to analyze public discussion boards on BabyCenter.com and WhattoExpect.com, to learn what factors motivate parents to either go ahead or delay vaccinating their children for diseases like measles and mumps, said Dominic Hein, executive director of the company unit that plans new vaccines. The two month project, conducted last year, collected only anonymized excerpts and topics from posts, and no user identities, the company said.

   The study concluded that parents often had a lack of “comfort” with the safety of shots, and were unconvinced that they needed to vaccinate their kids against diseases like measles and mumps. The text analytics software allowed Glaxo to gather the themes of thousands of posts into topical clusters like “safety,” “timing” and “comfort” and sentiments, like “happiness” and “unhappiness,” giving the company a broader, more candid view than what parents might express through an official survey or focus group…

http://blogs.wsj.com/cio/2013/05/01/glaxo-mined-online-parent-discussion-boards-for-vaccine-worries/